TICKERNERD
Menu
GUTSGUTSHealthcare · Biotechnology

GUTS Stock Forecast: Fractyl Health, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.98
−1.59% on the day

The 6 Wall Street analysts covering Fractyl Health, Inc. hold a median 12-month price target of $39 — +3895.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 22 of 100 as at 29 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$13.2M
Ticker Nerd rank
22/ 100
Median analyst target
$39
Analysts covering
6
Revenue$0.0
Operating income−$19.1M
Net income−$25.5M
Free cash flow−$15.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.6%
1M
−85.0%
YTD
−96.3%
1Y
−93.4%
From 52W high
−96.6%
From 52W low
+10.9%
$1
$28
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GUTS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Fractyl Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 29 Oct 2026
22/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Accruals
76
Growth
69
Issuance
40
Revisions
36
Momentum
8
Quality
8
Volatility
7
Value
4

Size (89): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GUTS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GUTS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Jan 26Apr 26Jul 26Oct 26GUTSHigh $72Median $39Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $5Median $39High $72

The green dot is the last close — the median target sits +3895.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Oct 2026Canaccord GenuityMaintainsBuy$96 → $39
19 Oct 2026Morgan StanleyMaintainsEqual-Weight$24 → $4.00
1 July 2026Craig-HallumInitiatesBuy$4.00
1 July 2026Craig-HallumInitiatesBuy—
4 June 2026HC Wainwright & Co.ReiteratesBuy—
24 Apr 2026HC Wainwright & Co.ReiteratesBuy—
26 Mar 2026Canaccord GenuityMaintainsBuy—
30 Jan 2026Morgan StanleyDowngradeEqual-Weight—
2 Dec 2025HC Wainwright & Co.ReiteratesBuy—
21 Nov 2025Canaccord GenuityMaintainsBuy—
26 Sept 2025HC Wainwright & Co.MaintainsBuy—
15 Sept 2025HC Wainwright & Co.InitiatesBuy—
28 Aug 2025Ladenburg ThalmannInitiatesBuy—
14 Aug 2025Canaccord GenuityMaintainsBuy—
15 Apr 2025Canaccord GenuityInitiatesBuy—
3 Feb 2025Morgan StanleyMaintainsOverweight—
28 Feb 2024Evercore ISI GroupInitiatesOutperform—
27 Feb 2024Morgan StanleyInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GUTS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GUTS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Fractyl Health, Inc. returned −93.4% against +12.4% for the S&P 500, dividends included.

GUTS vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26GUTSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GUTS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Fractyl Health, Inc. (GUTS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.1×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
−94.5×

Cheaper than 99% of US stocks

EV / EBITDA
−0.3×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1490.3%

Higher than 1% of US stocks

Return on assets
−74.6%

Higher than 4% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Fractyl Health, Inc. (GUTS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Fractyl Health, Inc. has a market value of $13.2M and an enterprise value of $26.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.7M.

  • Diluted earnings per share, trailing twelve months: $−1.10.

  • Free cash flow in the twelve months to 30 June 2026: −$82.4M.

  • Shares outstanding: 158.6M.

  • Trailing P/E: −1.1×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Fractyl Health, Inc. employs 100 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

GUTS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GUTSFractyl Health, Inc.$13.2M22
ATYRaTyr Pharma, Inc.$13.2M59
DAREDaré Bioscience, Inc.$13.2M30
CNSYCerenome, Inc.$13.2M15
AZRAzora Therapeutics, Inc.$12.8M22
TCRXTScan Therapeutics, Inc.$12.7M54
PBMPsyence Biomedical Ltd.$13.8M4

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Fractyl Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GUTS news & analysis

Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization

GlobeNewsWire · 30 Oct 2026positive

Fractyl Health announced additions to its U.S. patent portfolio for investigational Revita as it advances toward a planned FDA De Novo marketing submission for post-GLP-1 weight maintenance.

Why it matters — The patent additions strengthen the intellectual property foundation for Revita as the company works toward a potential U.S. regulatory submission and commercialization.

Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance

GlobeNewsWire · 29 Oct 2026positive

Fractyl Health reported company-sponsored market research indicating that one-third of surveyed GLP-1 users preferred an endoscopic procedure over continued medication. Respondents most often cited a one-time procedure and freedom from daily or weekly medication as positive attributes; the company said the findings support commercial planning for Revita.

Why it matters — The research offers insight into potential patient interest relevant to Fractyl’s commercial planning for Revita, though the excerpt provides no further study details.

Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

GlobeNewsWire · 22 Oct 2026neutral

Fractyl Health said it will concentrate resources on Revita following positive six-month topline results from the REMAIN-1 pivotal study, with a planned FDA De Novo submission in late Q4 2026 and 12-month pivotal data expected in Q1 2027. The company is discontinuing development of Rejuva candidates, seeking strategic alternatives for its Rejuva gene therapy program, and reducing its workforce; it expects cash runway into Q2 2027 and quarterly operating cash burn of about $8 million by the end of that quarter.

Why it matters — The update outlines a strategic shift toward Revita and provides GUTS watchers with planned regulatory and data milestones alongside changes to spending and the Rejuva program.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS

GlobeNewsWire · 19 Oct 2026negative

A lawsuit names Fractyl Health CEO Harith Rajagopalan and former CFO Lisa A. Davidson in Section 20(a) control person claims concerning allegedly overstated Revita DMR efficacy data. The notice states that GUTS shares lost approximately 74.86% of their value over two trading days and identifies October 20, 2026, as the lead plaintiff deadline.

Why it matters — The claims and reported share decline are relevant to GUTS watchers following the company's legal and market developments.

FAQ

Frequently asked questions about GUTS stock

What is the GUTS stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Fractyl Health, Inc. have a median 12-month price target of $39, with estimates ranging from $5 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GUTS stock a buy right now?

Of the 6 analysts covering Fractyl Health, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Fractyl Health, Inc. 22 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GUTS?

As at 29 Oct 2026, Fractyl Health, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will GUTS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +3895.1% from the last close, and Ticker Nerd's factor model ranks Fractyl Health, Inc. 22 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GUTS stock forecast for 2030?

No analyst covering Fractyl Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GUTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $72 over the next 12 months.

How has GUTS stock performed over the past year?

Fractyl Health, Inc. returned -93.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Fractyl Health, Inc. do?

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for obesity and type 2 diabetes.

What is the latest news on GUTS?

The most recent item we track (GlobeNewsWire, 30 Oct 2026): "Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization". Fractyl Health announced additions to its U.S. patent portfolio for investigational Revita as it advances toward a planned FDA De Novo marketing submission for post-GLP-1 weight maintenance.

Company

About Fractyl Health, Inc.

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing treatments for obesity and type 2 diabetes. Its current work centers on approaches that address the root causes of metabolic disease rather than only managing symptoms, with a primary emphasis on gut-based therapies. The company’s lead product candidate, Revita, is an investigational outpatient procedural therapy designed to remodel dysfunctional duodenal tissue and improve metabolic signaling. Fractyl Health is also developing Rejuva, a pancreatic gene therapy platform aimed at supporting longer-term metabolic control. Based in Burlington, Massachusetts, Fractyl Health operates in the healthcare and biotechnology space, where it is working on device- and therapy-based solutions for serious chronic metabolic conditions.

CEO Dr. Harith Rajagopalan M.D., Ph.D. · 100 employees · United States · https://fractyl.com